[ Price : $8.95]
FDA accepts for priority review a Takeda and Protagonist Therapeutics NDA for rusfertide, positioning the drug as a potential firs...[ Price : $8.95]
Pfizer CEO Albert Bourla tells TD Cowen healthcare conference that the leadership of FDAs biologics center is worrisome because it...[ Price : $8.95]
FDA removes a clinical hold against Intellia Therapeutics and its MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z), an expe...[ Price : $8.95]
Three former senior FDA officials tell a federal appeals court that the Trump administration mischaracterized the science on contr...[ Price : $8.95]
HHS directs FDA and other health agency employees to immediately stop using the artificial intelligence platform Claude after the ...[ Price : $8.95]
FDA approves a Synergy Spine Solutions PMA for its Synergy Disc, a motion-preserving artificial cervical disc.[ Price : $8.95]
A leading myeloma researcher says FDAs draft guidance endorsing minimal residual disease as a potential basis for accelerated drug...[ Price : $8.95]
Drug user fee negotiators confront lingering divisions over FDAs America First proposals and the structure of hiring commitments, ...